Bluejay diagnostics announces $1.59 million registered direct offering priced at-the-market under nasdaq rules

Acton, mass., aug. 25, 2023 (globe newswire) -- bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay” or the “company”), a medical technology company developing rapid diagnostics on its symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into a definitive agreement for the purchase and sale of 216,000 shares of the company's common stock at a purchase price of $7.365 per share of common stock in a registered direct offering priced at-the-market under nasdaq rules. in addition, in a concurrent private placement, the company will issue unregistered warrants to purchase up to 216,000 shares of its common stock. the warrants will have an exercise price of $7.24 per share and will be immediately exercisable upon issuance for a period of five years. the closing of the registered direct offering and the concurrent private placement is expected to occur on or about august 28, 2023, subject to the satisfaction of customary closing conditions.
BJDX Ratings Summary
BJDX Quant Ranking